Compare Mesoblast Limited (MESO) vs Mondaycom Ltd (MNDY) Price & Performance

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Monday.com (MNDY) trades at $84.4, down 4.76% amid mixed signals. The stock shows strong fundamentals with Q2 2026 EPS of $1.48 beating estimates by 33%, revenue growth of 22% year-over-year, and a high gross margin of 88.74%. However, weak Q3 revenue guidance has triggered a sell-off. Technical indicators are neutral with support at $83 and resistance at $89. Analyst consensus remains bullish with a $113.38 price target, but near-term volatility persists due to growth concerns.

The outlook is cautiously optimistic given solid earnings beats and AI product traction, but investor sentiment is tempered by slowing revenue guidance. Key risks include SaaS sector pressures and execution challenges in shifting to enterprise AI. Upside potential exists if the company exceeds Q3 expectations, though volatility may continue until growth reaccelerates.